{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017194","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.991438+00:00","generated_at":"2026-06-16T00:55:01.515569+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptive Biotechnologies Q1 net loss $57.7M; clonoSEQ volume up 57% YoY","bullets":["Revenue $37.6M (-3% YoY); MRD $21.4M (+20%); Immune Medicine $16.2M (-22% due to Genentech amortization decline).","clonoSEQ test volume 12,079 (+57% YoY); new Takeda pan-portfolio collaboration for MRD endpoint.","Net loss $57.7M (vs $62.8M prior); Adjusted EBITDA loss $37.1M (vs $43.1M prior).","FY2023 revenue guidance reaffirmed $205M-$215M; expects OpEx below FY2022 level of $385.5M.","Consolidation of President and COO roles under Julie Rubinstein."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017194","json":"https://secwatch.observer/filing/0000950170-23-017194.json","markdown":"https://secwatch.observer/filing/0000950170-23-017194.md","text":"https://secwatch.observer/filing/0000950170-23-017194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/0000950170-23-017194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/adpt-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:55:01.515569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aab8f3604090a2f3aaccfb1c98729a9467a139da","claim":"Adaptive Biotechnologies Corp reported the quarter ended March 31, 2023 results: revenue $37.6 million, net income Net loss was $57.7 million. Guidance reaffirmed.","evidence_excerpt":"goals in both MRD and Immune Medicine and remain committed to drive operational efficiencies while managing capital allocation to support growth.” Recent Highlights • Revenue of $37.6 million for the first quarter 2023, representing a 3% decrease from $38.6 million in the first quarter 2022, which reflects the expected $3.2 million decline in amortization of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023017194/0000950170-23-017194-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$37.6 million"},{"label":"Net income","value":"Net loss was $57.7 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}